'In the ideal position': Neuren Pharmaceuticals books profit and looks to second treatment after positive results
Subscribe to BusinessDesk
Stay informed on business, government and financial developments across New Zealand.
- Deeply researched, twice-edited and fact-checked news
- Annual subscribers also receive a complimentary subscription to The Wall Street Journal
- Personalised email news alerts, plus gift up to 5 stories a month to non-subscribers
You can cancel anytime with two clicks, an email or a phone call.
Find out more.
We are serious about journalism.
Already a Subscriber ? Sign in here.
All subscriptions auto renew but are easy to cancel.
Total Price Including Tax: {{ priceWithTax(selectedPlan) | currency }} {{ selectedPlan.type == 'user' && spark.chargesUsersPerSeat ? '/ '+ spark.seatName : '' }} {{ selectedPlan.type == 'user' && spark.chargesUsersPerTeam ? '/ '+ __('teams.team') : '' }} / {{ __(selectedPlan.interval) | capitalize }}
Not convinced yet?
Subscribe to our free 7am Headlines newsletter.
A quick summary of everything BusinessDesk has published in the previous 24 hours. No BusinessDesk
subscription needed.
Tourism Holdings stalls as NZ sharemarket ends week on high
The NZ sharemarket bounced back as large-cap stocks balanced gains and losses.
Wikeley loses again in Owen Glenn stoush
Supreme Court says fraud findings can’t be relitigated.
Forsyth Barr shifts Turners Automotive to neutral
The company has delivered five consecutive years of record earnings.
Tough conversations ahead as cost of living drives employee requests for pay rises
Rising living costs put pressure on both workers and employers.
Why corporate giving matters
Dave Letele and Z provide support where urgent need is overlooked.
